| Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ... New England Journal of Medicine 349 (15), 1423-1432, 2003 | 1596 | 2003 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1528 | 2006 |
| Long-term outcomes of imatinib treatment for chronic myeloid leukemia A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ... New England Journal of Medicine 376 (10), 917-927, 2017 | 1246 | 2017 |
| Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia A Hochhaus, SG O'brien, F Guilhot, BJ Druker, S Branford, L Foroni, ... Leukemia 23 (6), 1054-1061, 2009 | 1133 | 2009 |
| International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data DA Arber, A Orazi, RP Hasserjian, MJ Borowitz, KR Calvo, HM Kvasnicka, ... Blood, The Journal of the American Society of Hematology 140 (11), 1200-1228, 2022 | 1091 | 2022 |
| Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding … S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ... Blood 102 (1), 276-283, 2003 | 990 | 2003 |
| Dynamics of chronic myeloid leukaemia F Michor, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers, ... Nature 435 (7046), 1267-1270, 2005 | 977 | 2005 |
| High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute … S Branford, Z Rudzki, S Walsh, A Grigg, C Arthur, K Taylor, R Herrmann, ... Blood, The Journal of the American Society of Hematology 99 (9), 3472-3475, 2002 | 908 | 2002 |
| Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, DT Yeung, ... Blood, The Journal of the American Society of Hematology 122 (4), 515-522, 2013 | 839 | 2013 |
| Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of … TP Hughes, A Hochhaus, S Branford, MC Müller, JS Kaeda, L Foroni, ... Blood, The Journal of the American Society of Hematology 116 (19), 3758-3765, 2010 | 621 | 2010 |
| Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis J Cortes, P Rousselot, DW Kim, E Ritchie, N Hamerschlak, S Coutre, ... Blood 109 (8), 3207-3213, 2007 | 571 | 2007 |
| Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) B Hanfstein, MC Müller, R Hehlmann, P Erben, M Lauseker, A Fabarius, ... Leukemia 26 (9), 2096-2102, 2012 | 510 | 2012 |
| Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase F Guilhot, J Apperley, DW Kim, EO Bullorsky, M Baccarani, GJ Roboz, ... blood 109 (10), 4143-4150, 2007 | 501 | 2007 |
| The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob, A Loo, P Furet, ... Nature 543 (7647), 733-737, 2017 | 492 | 2017 |
| Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient … S Branford, L Fletcher, NCP Cross, MC Müller, A Hochhaus, DW Kim, ... Blood, The Journal of the American Society of Hematology 112 (8), 3330-3338, 2008 | 467 | 2008 |
| Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency NP Shah, BJ Skaggs, S Branford, TP Hughes, JM Nicoll, RL Paquette, ... The Journal of clinical investigation 117 (9), 2562-2569, 2007 | 449 | 2007 |
| Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase T Hughes, G Saglio, S Branford, S Soverini, DW Kim, MC Müller, ... Journal of clinical oncology 27 (25), 4204, 2009 | 389 | 2009 |
| Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations MC Müller, JE Cortes, DW Kim, BJ Druker, P Erben, R Pasquini, ... Blood, The Journal of the American Society of Hematology 114 (24), 4944-4953, 2009 | 349 | 2009 |
| Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in … JE Cortes, M Baccarani, F Guilhot, BJ Druker, S Branford, DW Kim, ... Journal of Clinical Oncology 28 (3), 424, 2010 | 345 | 2010 |
| Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, PA Bartley, ... Leukemia 24 (10), 1719-1724, 2010 | 337 | 2010 |
